May 22 Clinical Quick Takes: Lilly's mirikizumab meets Crohn's endpoints; plus Novartis, 89bio and more

Lilly's mirikizumab meets in Phase II for Crohn’s
Mirikizumab (LY3074828) from Eli Lilly and Co. (NYSE:LLY) met the primary and secondary endpoints of improving clinical and endoscopic measures of disease activity at week

Read the full 321 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE